

Stefan Suci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8751688/publications.pdf>

Version: 2024-02-01

18
papers

5,211
citations

516710

16
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

5401
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic and predictive value of β -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2022, 165, 97-112.	2.8	18
2	Reply to E. Hindi. <i>Journal of Clinical Oncology</i> , 2021, 39, 944-946.	1.6	1
3	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 655-664.	10.7	37
4	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654.	10.7	224
5	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2021, 158, 156-168.	2.8	19
6	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. <i>JAMA Oncology</i> , 2020, 6, 519.	7.1	287
7	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3925-3936.	1.6	192
8	Adjuvant therapy with pegylated interferon- α 2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. <i>European Journal of Cancer</i> , 2020, 133, 94-103.	2.8	13
9	Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. <i>Journal of Clinical Oncology</i> , 2020, 38, 2543-2551.	1.6	40
10	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 119, 1-10.	2.8	132
11	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019, 116, 148-157.	2.8	64
12	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1789-1801.	27.0	1,441
13	Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage IIâ€“III Melanoma Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 87-96.	6.3	89
14	Adjuvant interferon- α for the treatment of high-risk melanoma: An individual patient data meta-analysis. <i>European Journal of Cancer</i> , 2017, 82, 171-183.	2.8	159
15	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016, 375, 1845-1855.	27.0	1,140
16	Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIâ€“III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. <i>European Journal of Cancer</i> , 2016, 55, 111-121.	2.8	80
17	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC) Tj ETQq1 1 0,784314 r&BT /Ove	10.7	1,093
18	Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. <i>European Journal of Cancer</i> , 2012, 48, 218-225.	2.8	182